ebook Munafa Stock Market Course + Intraday & FNO calls  

       

RDY announcements Dr. Reddy's Laboratories Ltd announcements and dividends declared USA

Dr. Reddy's Laboratories Ltd Complete list of announcements declared & dividend announcements by Dr. Reddy's Laboratories Ltd RDY

Dr. Reddy's Laboratories Ltd RDY listed on USA and deals in Health Care Major Pharmaceuticals

Announcements and dividends declared by Dr. Reddy's Laboratories Ltd RDY

Dr Reddy’s inks licensing deal to sell Immutep’s cancer drug
Dr. Reddy's Laboratories has secured an exclusive licensing agreement with Immutep to manufacture, develop, and distribute the Australian company's cancer therapy, eftilagimod alfa. This significant deal, valued at up to 0 million, grants Dr. Reddy's di
Announcement as on 08 December 2025

India weight-loss market reset? In setback for Novo Nordisk, Dr Reddy's Lab allowed to make semaglutide
The order follows the court’s view that Novo Nordisk’s patent appears prima facie invalid -- a finding that could reshape competitive dynamics in a market valued at around Rs 850 crore.
Announcement as on 03 December 2025

HC lets Dr Reddy's Laboratories export Semaglutide, blocks India sales till March '26
The Delhi High Court has permitted Dr Reddy's Laboratories to produce and export its version of the diabetes and anti-obesity drug semaglutide. This decision comes amidst a patent infringement case filed by Novo Nordisk. Dr Reddy's is restricted from selli
Announcement as on 03 December 2025

Stocks in news: Dr Reddy's, GAIL, Hudco, HUL, Acme Solar
Indian markets experienced a subdued trading session, closing nearly half a percent lower due to global uncertainties and continued FII selling. With the monthly expiry approaching, volatility is expected to remain high. Investors are advised to maintain a
Announcement as on 25 November 2025

Dr Reddy's gets European nod for biosimilar to treat osteoporosis
Prolia is a prescription medicine used to treat osteoporosis in women who have been through menopause and in men who are at increased risk of fractures, bone loss linked to hormone ablation in men with prostate cancer at increased risk of fractures and bon
Announcement as on 24 November 2025

Announcements by Dr. Reddy's Laboratories Ltd first page | Next page |

RDY Dr. Reddy's Laboratories Ltd current price & indicator signals

Moving Averages for Dr. Reddy's Laboratories Ltd

  • 5Day Average: 13.94
  • 12Day Average: 14.06
  • 20Day Average: 14.01
  • 50Day Average: 13.92
  • 100Day Average: 14.14
  • 150Day Average: 14.35
  • 200Day Average: 14.19

RDY Indicators & signals

Indicator MACD (12,26,9)

13.99, 14.01, 0
Indicator MACD is in negative zone

Indicator ADX (14)

6.67, 38.1, 33.33
Indicator ADX is indicating that momentum is weak.
Indicator ADX is showing that momentum is towards buying

Indicator RSI (14)

Current RSI is: 39
Indicator RSI is indicating selling pressure and stock might fall.

Recent prices of RDY Dr. Reddy's Laboratories Ltd are as follows: Daily volume is divided by 10 day averaged volume

Date Close Range Change % Volume
06 Tue Jan 2026 13.86 13.83 to 14.12 0.29% 1.54 times
05 Mon Jan 2026 13.82 13.74 to 13.88 -0.29% 1.28 times
02 Fri Jan 2026 13.86 13.66 to 13.92 -1.35% 1.36 times
31 Wed Dec 2025 14.05 14.01 to 14.16 -0.43% 0.5 times
29 Mon Dec 2025 14.11 14.06 to 14.16 0% 0.72 times
29 Mon Dec 2025 14.11 14.06 to 14.16 -0.35% 0.72 times
26 Fri Dec 2025 14.16 14.08 to 14.20 0.5% 1.14 times
24 Wed Dec 2025 14.09 14.03 to 14.12 -0.98% 0.43 times
23 Tue Dec 2025 14.23 14.17 to 14.32 -0.28% 1.18 times
22 Mon Dec 2025 14.27 14.12 to 14.27 0.63% 1.04 times
19 Fri Dec 2025 14.18 14.01 to 14.24 1.72% 1.63 times
18 Thu Dec 2025 13.94 13.93 to 14.06 0.07% 2.37 times

Videos related to: RDY announcements Dr. Reddy's Laboratories Ltd announcements and dividends declared USA

Hindi Video Correct Way Of Fundamental Analysis Using EPS And PE - MunafaSutra

Hindi Video What Is Needed To Succeed In Stock Markets

RDY announcements Dr. Reddy's Laboratories Ltd announcements and dividends declared USA

 

Back to top